Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth.

Cook MR, Pinchot SN, Jaskula-Sztul R, Luo J, Kunnimalaiyaan M, Chen H.

Mol Cancer Ther. 2010 Feb;9(2):429-37. doi: 10.1158/1535-7163.MCT-09-0718.

2.

The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors?

Kunnimalaiyaan M, Chen H.

Anticancer Drugs. 2006 Feb;17(2):139-42. Review.

PMID:
16428931
3.

Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.

Fragoso YD, Brooks JB.

Expert Rev Clin Pharmacol. 2015 May;8(3):315-20. doi: 10.1586/17512433.2015.1019343. Review.

PMID:
25712857
4.

Comparison of two molecular scaffolds, 5-methylisoxazole-3-carboxamide and 5-methylisoxazole-4-carboxamide.

Song Y, Zhang Y, Lee AR, Huang WH, Chen B, Palfey B, Shaw J.

Curr Pharm Des. 2014;20(1):146-52. Review.

PMID:
23944378
5.

Gastrointestinal carcinoid tumours. Histogenetic, histochemical, immunohistochemical, clinical and therapeutic aspects.

Wilander E, Lundqvist M, Oberg K.

Prog Histochem Cytochem. 1989;19(2):1-88. Review.

PMID:
2662260
6.

Raf kinase as a target for anticancer therapeutics.

Sridhar SS, Hedley D, Siu LL.

Mol Cancer Ther. 2005 Apr;4(4):677-85. Review.

7.

Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract.

Rorstad O.

J Surg Oncol. 2005 Mar 1;89(3):151-60. Review.

PMID:
15719376

Supplemental Content

Support Center